BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fujii T, Nozaki F, Saito K, Hayashi A, Nishigaki Y, Murayama K, Tanaka M, Koga Y, Hiejima I, Kumada T. Efficacy of pyruvate therapy in patients with mitochondrial disease: a semi-quantitative clinical evaluation study. Mol Genet Metab 2014;112:133-8. [PMID: 24830361 DOI: 10.1016/j.ymgme.2014.04.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Cui Y, Jiang D, Ma C, Tse H, Hwu W, Lian Q. Management of Leigh syndrome: Current status and new insights. Clinical Genetics 2018;93:1131-40. [DOI: 10.1111/cge.13139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kemppainen E, George J, Garipler G, Tuomela T, Kiviranta E, Soga T, Dunn CD, Jacobs HT. Mitochondrial Dysfunction Plus High-Sugar Diet Provokes a Metabolic Crisis That Inhibits Growth. PLoS One 2016;11:e0145836. [PMID: 26812173 DOI: 10.1371/journal.pone.0145836] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
3 Tiet MY, Lin Z, Gao F, Jennings MJ, Horvath R. Targeted Therapies for Leigh Syndrome: Systematic Review and Steps Towards a 'Treatabolome'. J Neuromuscul Dis 2021. [PMID: 34308912 DOI: 10.3233/JND-210715] [Reference Citation Analysis]
4 Lehmann D, Mcfarland R. Overview of Approaches to Mitochondrial Disease Therapy. Journal of Inborn Errors of Metabolism and Screening 2018;6:232640981775296. [DOI: 10.1177/2326409817752960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Gucek M, Sack MN. Proteomic and metabolomic advances uncover biomarkers of mitochondrial disease pathophysiology and severity. J Clin Invest 2021;131:145158. [PMID: 33463543 DOI: 10.1172/JCI145158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rossignol R. Energy metabolism disorders in rare and common diseases. Toward bioenergetic modulation therapy and the training of a new generation of European scientists. Int J Biochem Cell Biol 2015;63:2-9. [PMID: 25595463 DOI: 10.1016/j.biocel.2015.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
7 Darbandi S, Darbandi M, Khorshid HR, Sadeghi MR, Al-Hasani S, Agarwal A, Shirazi A, Heidari M, Akhondi MM. Experimental strategies towards increasing intracellular mitochondrial activity in oocytes: A systematic review. Mitochondrion 2016;30:8-17. [PMID: 27234976 DOI: 10.1016/j.mito.2016.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
8 Patgiri A, Skinner OS, Miyazaki Y, Schleifer G, Marutani E, Shah H, Sharma R, Goodman RP, To TL, Robert Bao X, Ichinose F, Zapol WM, Mootha VK. An engineered enzyme that targets circulating lactate to alleviate intracellular NADH:NAD+ imbalance. Nat Biotechnol 2020;38:309-13. [PMID: 31932725 DOI: 10.1038/s41587-019-0377-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
9 Ciesielski GL, Hytönen VP, Kaguni LS. Biolayer Interferometry: A Novel Method to Elucidate Protein-Protein and Protein-DNA Interactions in the Mitochondrial DNA Replisome. Methods Mol Biol 2016;1351:223-31. [PMID: 26530686 DOI: 10.1007/978-1-4939-3040-1_17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
10 Sharma R, Reinstadler B, Engelstad K, Skinner OS, Stackowitz E, Haller RG, Clish CB, Pierce K, Walker MA, Fryer R, Oglesbee D, Mao X, Shungu DC, Khatri A, Hirano M, De Vivo DC, Mootha VK. Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity. J Clin Invest 2021;131:136055. [PMID: 33463549 DOI: 10.1172/JCI136055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
11 Smeitink J, van Maanen R, de Boer L, Ruiterkamp G, Renkema H. A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC"). BMC Neurol 2022;22:158. [PMID: 35477351 DOI: 10.1186/s12883-022-02685-3] [Reference Citation Analysis]
12 Radelfahr F, Klopstock T. [Mitochondrial diseases]. Nervenarzt 2019;90:121-30. [PMID: 30643957 DOI: 10.1007/s00115-018-0666-2] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Burgin HJ, Lopez Sanchez MIG, Smith CM, Trounce IA, McKenzie M. Pioglitazone and Deoxyribonucleoside Combination Treatment Increases Mitochondrial Respiratory Capacity in m.3243A>G MELAS Cybrid Cells. Int J Mol Sci 2020;21:E2139. [PMID: 32244971 DOI: 10.3390/ijms21062139] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Barcelos I, Shadiack E, Ganetzky RD, Falk MJ. Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines. Curr Opin Pediatr 2020;32:707-18. [PMID: 33105273 DOI: 10.1097/MOP.0000000000000954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
15 Li M, Zhou S, Chen C, Ma L, Luo D, Tian X, Dong X, Zhou Y, Yang Y, Cui Y. Therapeutic potential of pyruvate therapy for patients with mitochondrial diseases: a systematic review. Ther Adv Endocrinol Metab 2020;11:2042018820938240. [PMID: 32695307 DOI: 10.1177/2042018820938240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang L, Garcia Canaveras JC, Chen Z, Wang L, Liang L, Jang C, Mayr JA, Zhang Z, Ghergurovich JM, Zhan L, Joshi S, Hu Z, McReynolds MR, Su X, White E, Morscher RJ, Rabinowitz JD. Serine Catabolism Feeds NADH when Respiration Is Impaired. Cell Metab 2020;31:809-821.e6. [PMID: 32187526 DOI: 10.1016/j.cmet.2020.02.017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 20.5] [Reference Citation Analysis]
17 Gerards M, Sallevelt SC, Smeets HJ. Leigh syndrome: Resolving the clinical and genetic heterogeneity paves the way for treatment options. Mol Genet Metab. 2016;117:300-312. [PMID: 26725255 DOI: 10.1016/j.ymgme.2015.12.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
18 Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis. Cell 2015;162:540-51. [PMID: 26232224 DOI: 10.1016/j.cell.2015.07.016] [Cited by in Crossref: 598] [Cited by in F6Publishing: 554] [Article Influence: 85.4] [Reference Citation Analysis]
19 Van Vranken JG, Rutter J. You Down With ETC? Yeah, You Know D! Cell 2015;162:471-3. [PMID: 26232217 DOI: 10.1016/j.cell.2015.07.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
20 Rao Y, Gammon ST, Sutton MN, Zacharias NM, Bhattacharya P, Piwnica-Worms D. Excess exogenous pyruvate inhibits lactate dehydrogenase activity in live cells in an MCT1-dependent manner. J Biol Chem 2021;297:100775. [PMID: 34022218 DOI: 10.1016/j.jbc.2021.100775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Sahenk Z, Yalvac ME, Amornvit J, Arnold WD, Chen L, Shontz KM, Lewis S. Efficacy of exogenous pyruvate in TremblerJ mouse model of Charcot-Marie-Tooth neuropathy. Brain Behav 2018;8:e01118. [PMID: 30239155 DOI: 10.1002/brb3.1118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Campolina-sampaio GP, Lasmar LMDLBF, Ribeiro BSV, Gurgel-giannetti J. The Newcastle Pediatric Mitochondrial Disease Scale: translation and cultural adaptation for use in Brazil. Arq Neuro-Psiquiatr 2016;74:909-13. [DOI: 10.1590/0004-282x20160137] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Koga Y, Povalko N, Inoue E, Nashiki K, Tanaka M. Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease. Mitochondrion 2019;48:11-5. [PMID: 30738201 DOI: 10.1016/j.mito.2019.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
24 Nagasaka H, Komatsu H, Inui A, Nakacho M, Morioka I, Tsukahara H, Kaji S, Hirayama S, Miida T, Kondou H, Ihara K, Yagi M, Kizaki Z, Bessho K, Kodama T, Iijima K, Saheki T, Yorifuji T, Honda A. Circulating tricarboxylic acid cycle metabolite levels in citrin-deficient children with metabolic adaptation, with and without sodium pyruvate treatment. Molecular Genetics and Metabolism 2017;120:207-12. [DOI: 10.1016/j.ymgme.2016.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]